Cargando…
Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses
Aortic stenosis is the most common valvular heart disease in the Western world. It is caused primarily by age-related degeneration and progressive calcification typically detected in patients 65 years and older. In patients presenting with symptoms of heart failure, the average survival rate is only...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791312/ https://www.ncbi.nlm.nih.gov/pubmed/26918310 http://dx.doi.org/10.1097/IMI.0000000000000232 |
_version_ | 1782421067500879872 |
---|---|
author | Barnhart, Glenn R. Shrestha, Malakh Lal |
author_facet | Barnhart, Glenn R. Shrestha, Malakh Lal |
author_sort | Barnhart, Glenn R. |
collection | PubMed |
description | Aortic stenosis is the most common valvular heart disease in the Western world. It is caused primarily by age-related degeneration and progressive calcification typically detected in patients 65 years and older. In patients presenting with symptoms of heart failure, the average survival rate is only 2 years without appropriate treatment. Approximately one half of all patients die within the first 2 to 3 years of symptom onset. In addition, the age of the patients presenting for aortic valve replacement (AVR) is increased along with the demographic changes. The Society of Thoracic Surgeons (STS) database shows that the number of patients older than 80 years has increased from 12% to 24% during the past 20 years. At the same time, the percentage of candidates requiring AVR as well as concomitant coronary bypass surgery has increased from 5% to 25%. Surgical AVR continues to be the criterion standard for treatment of aortic stenosis, improving survival and quality of life. Recent advances in prosthetic valve technology, such as transcatheter AVR, have expanded the indication for AVR to the extreme high-risk population, and the most recent surgical innovation, rapid deployment AVR, provides an additional tool to the surgeons’ armamentarium. |
format | Online Article Text |
id | pubmed-4791312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-47913122016-04-05 Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses Barnhart, Glenn R. Shrestha, Malakh Lal Innovations (Phila) Review Article Aortic stenosis is the most common valvular heart disease in the Western world. It is caused primarily by age-related degeneration and progressive calcification typically detected in patients 65 years and older. In patients presenting with symptoms of heart failure, the average survival rate is only 2 years without appropriate treatment. Approximately one half of all patients die within the first 2 to 3 years of symptom onset. In addition, the age of the patients presenting for aortic valve replacement (AVR) is increased along with the demographic changes. The Society of Thoracic Surgeons (STS) database shows that the number of patients older than 80 years has increased from 12% to 24% during the past 20 years. At the same time, the percentage of candidates requiring AVR as well as concomitant coronary bypass surgery has increased from 5% to 25%. Surgical AVR continues to be the criterion standard for treatment of aortic stenosis, improving survival and quality of life. Recent advances in prosthetic valve technology, such as transcatheter AVR, have expanded the indication for AVR to the extreme high-risk population, and the most recent surgical innovation, rapid deployment AVR, provides an additional tool to the surgeons’ armamentarium. Lippincott Williams & Wilkins 2016-01 2016-02-25 /pmc/articles/PMC4791312/ /pubmed/26918310 http://dx.doi.org/10.1097/IMI.0000000000000232 Text en Copyright © 2016 by the International Society for Minimally Invasive Cardiothoracic Surgery This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Review Article Barnhart, Glenn R. Shrestha, Malakh Lal Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses |
title | Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses |
title_full | Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses |
title_fullStr | Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses |
title_full_unstemmed | Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses |
title_short | Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses |
title_sort | current clinical evidence on rapid deployment aortic valve replacement: sutureless aortic bioprostheses |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791312/ https://www.ncbi.nlm.nih.gov/pubmed/26918310 http://dx.doi.org/10.1097/IMI.0000000000000232 |
work_keys_str_mv | AT barnhartglennr currentclinicalevidenceonrapiddeploymentaorticvalvereplacementsuturelessaorticbioprostheses AT shresthamalakhlal currentclinicalevidenceonrapiddeploymentaorticvalvereplacementsuturelessaorticbioprostheses |